Showing results (11-20 of 20) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
The American Journal of Gastroenterology|March 23, 2016
Poor Correlation Between Clinical Disease Activity and Mucosal Inflammation, and the Role of Psychological Comorbidity, in Inflammatory Bowel DiseaseDavid J Gracie, Christopher J M Williams, Ruchit Sood, et al.Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 19, 2016
Negative Effects on Psychological Health and Quality of Life of Genuine Irritable Bowel Syndrome-type Symptoms in Patients With Inflammatory Bowel DiseaseDavid J Gracie, Christopher J M Williams, Ruchit Sood, et al.Inflammatory Bowel Diseases|April 19, 2018
No Significant Association Between the Fecal Microbiome and the Presence of Irritable Bowel Syndrome-type Symptoms in Patients with Quiescent Inflammatory Bowel DiseaseOliver Shutkever, David J Gracie, Caroline Young, et al.BMJ Open Gastroenterology|July 14, 2018
Golimumab induction and maintenance for moderate to severe ulcerative colitis: results from GO-COLITIS (Golimumab: a Phase 4, UK, open label, single arm study on its utilization and impact in ulcerative Colitis)Christopher Sj Probert, Shaji Sebastian, Daniel R Gaya, et al.Therapeutic Advances in Chronic Disease|April 3, 2019
Randomized controlled trial: a pilot study of a psychoeducational intervention for fatigue in patients with quiescent inflammatory bowel diseaseAnthony O'Connor, Raguprakash Ratnakumaran, Lisa Warren, et al.Inflammatory Bowel Diseases|November 16, 2017
Infliximab Therapeutic Drug Monitoring Changes Clinical Decisions in a Virtual Biologics Clinic for Inflammatory Bowel DiseaseChristian P Selinger, Marco V Lenti, Tanya Clark, et al.Journal of Crohn'S & Colitis|October 17, 2013
Costs of adalimumab versus infliximab as first-line biological therapy for luminal Crohn's diseaseGrace K H Choi, Stephanie D E Collins, Daniel P Greer, et al.Therapeutic Advances in Gastroenterology|February 1, 2018
Factors affecting clinical decision-making in inflammatory bowel disease and the role of point-of-care calprotectinYannick Derwa, Christopher J M Williams, Ruchit Sood, et al.Scandinavian Journal of Gastroenterology|April 25, 2018
Efficacy and tolerability of initiating, or switching to, infliximab biosimilar CT-P13 in inflammatory bowel disease (IBD): a large single-centre experienceRaguprakash Ratnakumaran, Natalie To, David J Gracie, et al.Inflammatory Intestinal Diseases|November 1, 2021
Infliximab Therapeutic Drug Monitoring in Inflammatory Bowel Disease Virtual Biologics Clinic Leads to Durable Clinical ResultsRebecca Sagar, Marco V Lenti, Tanya Clark, et al.Pageof 2